RADBIO combines the expertise of biotechnologists and medical specialists to convert scientific knowledge into therapeutic products. Their proprietary discoveries and technologies are used to create effective medical strategies for diseases such as rheumatoid arthritis, liver fibrosis, and cancer. The company's biomolecule, which neutralizes TGF-β, shows promise as a therapy for fibrotic disorders and solid tumors. Founded in 2018 and based in Wilmington, Delaware, RADBiotech aims to address unmet medical needs in various indications.